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ABSTRACT 19	  
 20	  
Understanding the complex mechanisms that govern the fate decisions of human embryonic stem 21	  
cells (hESCs) is fundamental to their use in cell replacement therapies. The progress of dissecting 22	  
these mechanisms will be facilitated by the availability of robust high-throughput screening 23	  
assays on hESCs. In this study, we report an image-based high-content assay for detecting 24	  
compounds that affect hESC survival or pluripotency. Our assay was designed to detect changes 25	  
in the phenotype of hESC colonies by quantifying multiple parameters, including the number of 26	  
cells in a colony, colony area and shape, intensity of nuclear staining, the percentage of cells in 27	  
the colony that express a marker of pluripotency (TRA-1-60), as well as the number of colonies 28	  
per well. We used this assay to screen 1040 compounds from two commercial compound 29	  
libraries, and identified 17 that promoted differentiation, as well as 5 that promoted survival of 30	  
hESCs. Among the novel small compounds we identified with activity on hESC, are several 31	  
steroids that promote hESC differentiation and the anti-hypertensive drug, Pinacidil, which 32	  
affects hESC survival. The analysis of overlapping targets of Pinacidil and the other survival 33	  
compounds revealed that activity of PRK2, ROCK, MNK1, RSK1 and MSK1 kinases may 34	  
contribute to the survival of hESCs. 35	  
36	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1. INTRODUCTION 36	  
 37	  
The derivation of human embryonic stem cell (hESC) lines opened up exciting opportunities for 38	  
their use in regenerative medicine, as hESCs can be maintained in culture in an undifferentiated 39	  
state, while retaining the ability to differentiate into somatic cell types [1]. Delineating the 40	  
molecular mechanisms that govern hESC self-renewal and differentiation to specific cell types is 41	  
critical to achieving the potential therapeutic benefits of hESC. Bioactive small molecules have 42	  
proven to be powerful probes for elucidating mechanisms underlying various cellular processes 43	  
[2]. Use of small molecules in cell-based phenotype screens provides an unbiased way of 44	  
dissecting relevant cellular pathways as this approach involves looking for a change in the cell 45	  
phenotype followed by analysis to identify molecular targets within the cell [3]. 46	  
Some small compounds have already been successfully applied to controlling stem cell 47	  
fates. Examples include a Rho-kinase inhibitor, Y-27632, which promotes survival of dissociated 48	  
hESCs [4], pluripotin, which promotes self-renewal of murine embryonic stem cells (ESCs) [3], 49	  
and stauprimide, which enhances the directed differentiation of ESCs [5]. Identifying further 50	  
compounds that can modulate various aspects of hESC biology would be beneficial for 51	  
improving hESC culture conditions, as well as for controlling differentiation to desired cell types. 52	  
Yet only a small number of high-throughput (HTS) screens have been performed on hESCs [6,7]. 53	  
A further shortcoming has been that as hESC growth characteristics are not readily amenable to 54	  
HTS set-ups, the published screens required significant adaptation of hESCs to make them 55	  
compatible with the HTS methodologies used, namely, assessing cells in a monolayer rather than 56	  
in their normal colony morphology. Such screens would inevitably lose potentially valuable 57	  
information about changes occurring in cultures after treatment with compounds. 58	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We have developed a high-content phenotype screen that can detect multiple effects of 59	  
small molecules on hESC in their natural in vitro state - as colonies. Our screening platform 60	  
combined automated imaging and analysis, enabling quantitative assessment of the phenotype in 61	  
a high-throughput fashion. We report the identification of several novel compounds that affected 62	  
hESC survival and pluripotency. 63	  
64	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2. RESULTS 64	  
 65	  
2.1. DEVELOPMENT OF A HIGH CONTENT ASSAY FOR hESC 66	  
We developed an image-based high-content assay using the InCell Analyzer (GE Healthcare) 67	  
automated microscopy system. The assay was designed to measure changes in morphological 68	  
features of hESC colonies as well as changes in their pluripotency status. To detect changes in 69	  
hESC pluripotency, we utilized the cell-surface marker TRA-1-60, which is down-regulated upon 70	  
differentiation [8, 9]. Firstly, we validated our assay using all-trans retinoic acid, a small 71	  
molecule known to induce differentiation of hESCs [9, 10]. Shef4 hESCs were dissociated to 72	  
single cells using Accutase and plated in 96-well plates in the presence of 10µM all-trans retinoic 73	  
acid or 0.1% DMSO (vehicle) as control. After 5 days of treatment, the cells were fixed, treated 74	  
with Hoechst 33342 to highlight nuclei and stained for TRA-1-60 expression. A reduction in 75	  
TRA-1-60 expression and morphological changes were seen in Shef4 colonies (Supplementary 76	  
Fig. S1).  77	  
Data from four fields were acquired from each well using a 4x objective (representing 78	  
46% of the total well area) for nuclear staining (Hoechst 33342) and TRA-1-60 (FITC) (Fig. 1a, 79	  
b, c). Automated image analysis software was then used to extract the multivariate data from the 80	  
acquired colony images. First, fluorescence of the nuclei (Fig. 1b) was used to identify cells in 81	  
the image, a process known as segmentation, followed by erosion of pixels identified at the edge 82	  
of each nuclei in the image to minimize overlapping of closely positioned nuclei (Fig. 1d). 83	  
Hoechst 33342 also stained nuclei of the feeder cells present. To exclude feeder cells from 84	  
images, all of the segmented objects in the image were expanded (dilated). This leads to merging 85	  
of hESC nuclei within a colony as they are positioned closely together. The resulting objects in 86	  
the image consisted of larger objects representing hESC colonies and smaller objects representing 87	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dilated feeder cell nuclei (Fig. 1e). The area of dilated objects and intensity of Hoechst 33342 88	  
staining (hESC nuclei stain brighter than feeder cells) were used as criteria to reject feeders and 89	  
leave only segmented hESC colonies in the images for further analysis (Fig. 1f). To determine 90	  
the percentage of TRA-1-60-positive hESCs in each field, the segmentation of the individual 91	  
nuclei (as shown in Fig. 1d) was used as a mask over the TRA-1-60 image (‘nuclear masking’, 92	  
Fig. 1g). This ensures unambiguous scoring of antibody staining in an individual cell. The cells 93	  
were assessed as positive for TRA-1-60 if the intensity of FITC signal was higher than the 94	  
threshold determined by the negative control on each plate (Fig. 1h). After filtering out feeders 95	  
from the image, the proportion of hESCs positive for TRA-1-60 was calculated by dividing the 96	  
number of hESCs positive for TRA-1-60 by total number of hESCs per field. This calculation 97	  
was necessary to circumvent false positive results that could arise as a consequence of the 98	  
changes in cell numbers alone. Apart from number of hESCs and percentage of TRA-1-60 99	  
positive cells per colony, various other parameters were measured, including number of colonies 100	  
per well, colony area, intensity of fluorescence of Hoechst 33342 nuclear staining (average 101	  
intensity of fluorescence over the segmented area) and form factor (a description of 2-102	  
dimensional shape, calculated as the ratio of the least diameter of the object to the largest where a 103	  
perfectly circular object would have the maximum value of 1) (Fig. 1i,j). 104	  
Treatment of Shef4 cells with all-trans retinoic acid for 5 days reduced the percentage of 105	  
TRA-1-60-expressing cells to less than 25%, similar to previously reported studies [9]. All-trans 106	  
retinoic acid-treated and control cells showed significant differences in most parameters 107	  
measured (Supplementary Table 1), reflecting the changes in morphology of hESC colonies 108	  
that accompany differentiation. The Z’ factor (a parameter assessing the quality of the assay [11]) 109	  
for the percentage of positive cells in replicate plates was >0.5,  indicating our assay was robust. 110	  
We then applied it to screening a library of small molecules. 111	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 112	  
2.2. HIGH-CONTENT SCREEN ON hESCs 113	  
Our primary screen on hESCs involved testing 1040 diverse compounds from two commercial 114	  
libraries: 80 compounds from a kinase inhibitor library and 960 compounds from the Prestwick 115	  
chemical library enriched with marketed drugs (Supplementary Table 2). All compounds were 116	  
tested in triplicate. Kinase inhibitors were tested at a commonly used concentration of 10µM, 117	  
whereas compounds from the Prestwick chemical library were tested at 2.5µg/ml (~5µM). Cell 118	  
numbers were used to assess cell viability upon treatment with a compound. Low cell numbers in 119	  
replicate wells (less than 40% of the control value) were taken as an indication of cytotoxicity 120	  
and such compounds were not pursued further in this study. After this filtering step, a 50% 121	  
reduction in proportion of TRA-1-60-positive cells was used as the criterion for identifying 122	  
compounds that induce differentiation.  123	  
We obtained 44 hits in the primary screen, with 28 compounds that decreased the 124	  
proportion of TRA-1-60-positive cells below 50% of the control value and 16 compounds that 125	  
increased cell numbers 50% above the control (Fig. 2a). Amongst the 28 hits that induced 126	  
differentiation was all-trans retinoic acid, which is included in the Prestwick library, providing 127	  
conformation of the robustness of our screen. A significant proportion of hits that caused 128	  
differentiation of hESCs belonged to the steroid class of compounds (13 steroids were amongst 129	  
the 28 hit compounds) (Fig. 2b) although steroids made up only 4.3% of the compounds tested. 130	  
Amongst the compounds that increased hESC numbers, kinase inhibitors were the most common 131	  
(4 kinase inhibitors out of 16 hits) (Fig. 2c) although they made up only 7.7% of the total number 132	  
of compounds tested. 133	  
To verify hits from the primary screen, compounds were re-tested on Shef4 hESCs. Re-134	  
testing the hits several times confirmed 17 compounds that decreased TRA-1-60 expression 135	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(Supplementary Table 3) and 5 compounds that increased cell numbers. Of these, four were 136	  
kinase inhibitors, Y-27632, HA1077, HA1004 and H-89, and they were also the most potent 137	  
amongst the compounds that increased cell numbers in the primary screen. The fifth compound 138	  
was a potassium channel opener used as an anti-hypertensive drug, Pinacidil (N-Cyano-N′-4-139	  
pyridinyl-N″-(1,2,2-trimethylpropyl)guanidine) [12, 13] (Fig. 2d). 140	  
 141	  
2.3. DIFFERENTIATION-INDUCING EFFECTS OF HITS 142	  
The hits that reduced TRA-1-60 marker expression in the primary screen were mainly 143	  
corticosteroid drugs, and some of these compounds were structural analogues of one another  – 144	  
e.g. prednisolone and 6-alpha methylprednisolone. Apart from reduced TRA-1-60 expression 145	  
(Fig. 2e) and a reduction in cell numbers (Fig. 2f), high-content data obtained in our primary 146	  
screen indicated that steroid treatment gave rise to a distinct morphology of hESC colonies. For 147	  
example, although the number of colonies was not significantly different from the control (Fig. 148	  
2g), steroid-treated cells were densely packed into small colonies, and this was reflected in a 149	  
smaller colony area (Fig. 2h) as well as increased intensity levels of Hoechst 33342 nuclear 150	  
staining (Fig. 2i). Furthermore, the steroid hits caused an increase in the form factor of colonies 151	  
(Fig. 2j) indicating that the Shef4-steroid treated colonies adopted a more circular morphology 152	  
(Fig. 2k). 153	  
 We selected four steroid hits from the primary screen, betamethasone, dexamethasone, 154	  
prednisolone and 6-alpha methylprednisolone, for follow-up analysis. First, we validated the 155	  
effects of these compounds on the loss of pluripotency using additional markers. Treated hESCs 156	  
showed a dose-dependant decrease of OCT4 levels (Fig. 3a and data not shown). We also 157	  
quantified the expression of SSEA3, TRA-1-60 and OCT4 using flow cytometry. Steroids 158	  
induced significant down-regulation of all three markers (Fig. 3b). However, some cells still 159	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retained expression of pluripotency markers after 7 days of treatment, indicating that steroid-160	  
treated cultures consist of a heterogeneous population of differentiated and pluripotent cells. To 161	  
further characterize the differentiated phenotype of these cells, RT-PCR analysis was performed 162	  
for a variety of lineage-specific markers, including MIXL, MSX1, EOMES, CDX2, CXCR4, 163	  
SOX7, PAX6 and HASH. Increased expression was seen for transcripts of trophoblast-associated 164	  
factors, EOMES and CDX2, as well as mesodermal markers MIXL and MSX1 (Fig. 3c). 165	  
 166	  
2.4. COMPOUNDS THAT INCREASED hESC NUMBERS 167	  
Amongst the compounds that increased hESC numbers in the primary screen were kinase 168	  
inhibitors Y-27632, HA1077, HA1004 and H-89, and the potassium channel opener Pinacidil. 169	  
We analyzed Pinacidil in more detail, as it has not been reported to have effects on hESCs. We 170	  
tested its effect on growth of hESC lines Shef4, Shef5, Shef6, Shef7 and H7S14 and observed 171	  
consistent increase of hESC numbers in all of the lines tested, indicating that the effect is not cell 172	  
line-specific (data not shown). Furthermore, a marked increase in hESC numbers was also noted 173	  
in feeder-free culture conditions on Matrigel, either in feeder-conditioned medium or in 174	  
chemically defined mTESR medium (Fig. 4a). Pinacidil exhibited a dose-dependent effect on 175	  
growth of Shef4 hESCs (Fig. 4b). At day 3 after plating and treatment, the number of cells was 176	  
already 3.5 times higher in wells with 100µM Pinacidil compared to the control (P=7.5x10-6, 177	  
Student’s t test). Even at the 12.5µM concentration, this effect was still significant (1.95-fold 178	  
more cells than control, P=4x10-5, Student’s t test).  179	  
Given that Pinacidil had a marked effect on cell numbers as early as 2 days after seeding, 180	  
we postulated that Pinacidil increases cell numbers by promoting survival or attachment of hESC 181	  
at the time of plating rather than affecting proliferation. To examine this further, we monitored 182	  
the attachment of cells upon treatment with 100µM and 10µM Pinacidil. Shef4 hESCs that 183	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expressed GFP were plated in 96-well plates on feeder cells and after removing unattached cells 184	  
by gentle washing the attached cells were imaged at 1,3 and 6 hours after plating. The appearance 185	  
of cells plated in the presence of 100µM Pinacidil was already markedly different 1 hour after 186	  
plating. They appeared more flattened out compared to the more rounded control cells. This 187	  
difference became even more pronounced at later time points (Fig. 4c). Both the number of 188	  
attached cells as well as the cell area from the images was quantified. A significant increase in 189	  
the number of attached cells was already observed 3 hours after plating in wells with 100µM 190	  
Pinacidil (Fig. 4d). Quantifying the average size (area) of attached cells, revealed a significant 191	  
increase at all three time points for 100µM Pinacidil and at 6 hours for 10µM Pinacidil (Fig. 4e). 192	  
This indicated that Pinacidil promotes attachment of hESCs. The higher number and better 193	  
attachment of cells in Pinacidil-treated samples could be due to a higher number of hESCs 194	  
surviving dissociation to single cells. Thus, we assessed whether Pinacidil reduces apoptosis by 195	  
staining cells for AnnexinV. Shef4 hESC were dissociated using trypsin and incubated in non-196	  
adhesive Petri dishes for 4 hours with or without Pinacidil. Control cells showed progressive 197	  
increase in the percentage of AnnexinV-positive cells over time, whereas this increase in 198	  
Pinacidil-treated cells occurred at a much slower rate (Fig. 4f), suggesting that Pinacidil prevents 199	  
apoptosis of dissociated hESCs. 200	  
To monitor further the differences in behaviour of single hESCs in Pinacidil-containing 201	  
media we used time-lapse microscopy. Shef4 cells were filmed for 72 hours from the time of 202	  
seeding  in either 0.1% DMSO or 100µM Pinacidil (Supplementary Fig. S2a). Tracking of 203	  
individual cells and analysis of their genealogies [14] (Supplementary Fig. S2b), suggested that 204	  
the majority of hESC plated in control conditions died after seeding, whereas Pinacidil 205	  
significantly improved survival rate of hESCs (Supplementary Fig. S2c). However, the time 206	  
between cell divisions was not significantly altered in Pinacidil-treated cells, indicating that 207	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Pinacidil does not alter the cell proliferation rate (Supplementary Fig. S2d). Thus, we concluded 208	  
that Pinacidil is acting as a pro-survival factor of hESCs. 209	  
The effects of Pinacidil on the pluripotency of hESCs were further examined. FACS 210	  
analysis of cell surface markers showed continued expression of the pluripotency-associated 211	  
markers SSEA3 and TRA-1-60, whereas the differentiation-associated marker SSEA1 was 212	  
reduced in 100µM Pinacidil-treated cells (Fig. 5a). Quantitative PCR analysis also showed an 213	  
increase in expression of POU5F1 (OCT4), and NANOG in cells treated with Pinacidil (Fig. 5b). 214	  
To confirm that Pinacidil did not adversely affect the differentiation capacity of hESCs, 215	  
Pinacidil-treated cells were assessed by inducing embryoid body (EB) formation in media with 216	  
no FGF and supplemented with 100µM Pinacidil. RT-PCR analysis after 15 days of EB culture 217	  
showed expression of various lineage markers, indicating that the hESCs remained capable of 218	  
differentiation (Fig. 5c). Furthermore, after eight passages in 100µM Pinacidil, cells continued to 219	  
express markers of the pluripotent state, POU5F1 (OCT4) and NANOG, and when induced to 220	  
differentiate through embryoid body formation, showed upregulation of lineage-specific markers 221	  
(Fig. 5d). Cells grown in the presence of 100µM Pinacidil for 22 passages retained a normal 222	  
karyotype (Fig. 5e). 223	  
To determine whether Pinacidil exerts its effects on hESCs through KATP channels as 224	  
reported for other cells, we first examined the expression of ABCC9 that encodes the Pinacidil-225	  
binding SUR2 subunit of KATP channels. Shef4 hESCs were sorted for the SSES3 pluripotency 226	  
marker to eliminate spontaneously differentiated cells in culture. We detected no expression of 227	  
ABCC9 at the mRNA level (Fig. 6a). Furthermore, the effect of Pinacidil could not be blocked by 228	  
using the KATP channel blocker glibenclamide (Fig. 6b). Finally, the effects of Pinacidil on hESC 229	  
numbers were not reproduced by using the Pinacidil analogue P1075, nor other KATP channel 230	  
openers for the SUR1 or SUR2 subunits (diazoxide, nicorandil, minoxidil, cromakalim) (Fig. 6c). 231	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Hence, our findings indicate that Pinacidil promotes survival of hESC through mechanisms that 232	  
are independent of its effects on KATP channels. 233	  
Given the striking similarity of the effect on hESCs of Pinacidil and the Rho-kinase 234	  
inhibitor Y-27632 (ROCKi), we reasoned that Pinacidil might also be inhibiting Rho-kinase 235	  
(ROCK). Indeed, Pinacidil showed a dose-dependant inhibition of ROCK, with only 9% activity 236	  
at 100µM Pinacidil (Fig.  6d). Furthermore, analysis of a panel of 105 kinases showed that  237	  
Pinacidil inhibited PRK2 and ROCK2 activity by more than 90%. Pinacidil also inhibited a 238	  
number of other kinases (Fig.  6e). 239	  
To compare Pinacidil with other survival compounds uncovered in our screen, we tested 240	  
their effect on hESC growth, using compounds in a range of concentrations from 1 to 100µM. 241	  
Kinase inhibitors Y-27632, HA1077, HA1004 and H-89 showed the highest effect at 25µM, 242	  
whereas Pinacidil showed its highest effect at 100µM. Y-27632 was the most potent compound 243	  
in increasing cell numbers (Fig. 7a). To determine whether any of the compounds could 244	  
synergize, each compound was used at its optimal concentration in combination with each of the 245	  
other compounds. No additive effects were observed (Fig. 7b). We also tested if kinase inhibitors 246	  
Y-27632, HA1077, HA1004 and H-89 could promote initial attachment of cells as Pinacidil does, 247	  
and observed an effect all of these compounds on initial cell attachment (Fig. 7c and 248	  
Supplementary Fig. S3a). No additive effect on cell attachment was observed when compounds 249	  
were used in combinations (Supplementary Fig. S3b). 250	  
In the light of the finding that Pinacidil inhibits ROCK2, we compared our kinase activity 251	  
data obtained for Pinacidil to similar published information available for Y-27632 ROCKi. 252	  
Pinacidil showed some overlapping targets with Y-27632 (Fig. 7d). Both compounds strongly 253	  
inhibited PRK2 and ROCK2. Other common targets included MNK1, RSK1, RSK2 and AMPK. 254	  
However, some of the kinases were inhibited by Pinacidil but not by Y-27632. These included 255	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PKCζ, MNK2, BRSK2, Aurora B, Erk8, S6K1 and CHK2. We extended this analysis using the 256	  
published data for HA1077 and H-89 [15] to compare the spectrum of targets altered by the four 257	  
compounds. Kinases were evident that were modulated by all 4 compounds, for example, PRK2, 258	  
ROCK, MNK1, RSK1 and MSK1 (Fig. 7e). Finally, given that ROCKi was the most potent of 259	  
the survival compounds uncovered in our screen, we looked for kinases that were uniquely 260	  
modulated by ROCKi compared to Pinacidil, HA1077 and H-89. There are two striking 261	  
differences. S6K1 and PKBα (AKT) are both strongly inhibited by Pinacidil, HA1077 and H-89 262	  
but not by ROCKi (Fig. 7e). 263	  
 264	  
3. DISCUSSION 265	  
In this study we have developed an image-based assay for analysis of the hESC colony 266	  
phenotype and have applied it to screening chemical libraries for compounds that can influence 267	  
the behaviour of hESCs. A key feature of our assay is an automated system for the simultaneous 268	  
quantification of multiple features of hESC colonies. This includes determining the number of 269	  
cells per colony, the number of colonies per well, the fluorescence intensity of nuclear staining, 270	  
the percentage of cells in the colony expressing a marker of pluripotency, as well as measuring 271	  
the colony area and shape. These parameters are important for assessing changes in hESC fate 272	  
upon compound treatment. For example, colony number is an indicator of cell survival rate at the 273	  
time of seeding, whereas cell number per colony reflects the proliferative capacity of the cells. 274	  
Furthermore, colony shape and cell density within a colony can change upon differentiation. 275	  
Such parameters provide indicators that complement the use of specific markers such as TRA-1-276	  
60 surface expression, which we used to monitor cell differentiation. This type of analysis was 277	  
previously limited to manual analysis on a low-throughput level. Our primary screen was, thus, 278	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fundamentally different from previous screens on hESCs as the combined readouts from our 279	  
assay could assess potential multiple effects of a compound on hESC colony phenotype in an 280	  
automated and quantifiable manner. 281	  
By using this image-based high-content assay we screened 1040 compounds that were 282	  
compiled from two commercial sources. We included a library of kinase inhibitors in our screen 283	  
because kinases are known to control a wide variety of cellular processes by regulating signalling 284	  
pathways through phosphorylation of target proteins [16]. The Prestwick library was enriched 285	  
with marketed drugs that were diverse both in structure and pharmacology. We identified 22 hits 286	  
in our screen – 17 that induced differentiation and 5 that increased hESC numbers. 287	  
Differentiation-inducing compounds were identified in the primary screen on the basis of 288	  
reduced expression of the TRA-1-60 marker of pluripotency. Corticosteroid compounds were the 289	  
predominate class of molecules to have this effect. Corticosteroids normally exert their function 290	  
through binding of steroid hormone receptors, which initiates a cascade of signalling events that 291	  
result in transcriptional control of target genes [17]. Treatment of cells with steroids induced 292	  
increased expression of trophoblast and mesoderm lineage markers. Dexamethasone has 293	  
previously been used in term villous explants to stimulate trophoblast differentiation and 294	  
maturation [18, 19] as well as to promote osteoblast differentiation from mouse ESCs [20]. By 295	  
promoting trophoblast and mesodermal differentiation programmes, steroids should provide 296	  
useful tools for lineage priming of hESCs. 297	  
Four of the five compounds identified to enhance the growth of hESCs were kinase 298	  
inhibitors. The fifth compound, Pinacidil, is a known agonist of ATP-sensitive potassium 299	  
channels (KATP) [12, 13, 21], and has not previously been linked to ESC growth. KATP channels 300	  
are expressed in a wide variety of excitable cells in which they couple the energy state of the cell 301	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to its membrane potential [22]. However, we could not detect the expression of the Pinacidil-302	  
binding subunit of KATP channels in undifferentiated hESCs, while other KATP channel agonists 303	  
failed to support hESC survival. The observed effects were not due to the dose of Pinacidil we 304	  
used as it is commonly used at 100µM in cell-based studies and its effects at this concentration 305	  
can be blocked by the KATP channel antagonist glibenclamide [23, 24]. However, glibenclamide 306	  
did not inhibit the ability of Pinacidil to promote hESC survival. This strongly suggested that 307	  
Pinacidil promotes hESC survival independently of its action on KATP channels. Indeed, we 308	  
showed that Pinacidil inhibits a number of kinases, such as Rho-kinase, which is known for its 309	  
role in mediating hESC survival [4,7]. 310	  
The reduction in the death rate amongst dissociated hESC by Pinacidil may have major 311	  
implications for many downstream applications of these cells. An emerging feature of hESC 312	  
biology is their inability to survive dissociation to single cells. The practical implication of this is 313	  
that hESCs are commonly passaged as clumps to increase their chance of survival. However, this 314	  
makes protocols for culturing and differentiation less robust, as colony size and spatial 315	  
distribution of colonies can affect signalling pathways in ESCs [25]. By using time-lapse imaging 316	  
we showed that Pinacidil increases survival rate of single hESC without leading to the formation 317	  
of multicellular clumps. Increased cell area of Pinacidil-treated cells early upon plating raises the 318	  
possibility that Pinacidil is modulating hESC survival through improved cell attachment. 319	  
Although Y-27632 ROCKi is often used in the stem cell field to promote survival of hESCs, it is 320	  
not an approved drug, and, therefore, not compatible with Good Manufacturing Practice for 321	  
clinical use of hESCs. Pinacidil, which has been approved by the FDA for clinical use, would 322	  
overcome these problems. 323	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Apart from their application in promoting hESC survival, the compounds uncovered in 324	  
our screen also present tools for dissecting molecular pathways involved in hESC death after 325	  
single cell dissociation. By examining a kinase selectivity profile of Pinacidil and comparing it 326	  
with the data published for three other survival compounds uncovered in our screen (Y-27632, 327	  
HA1077 and H-89) we identified some overlapping and some unique kinase targets for all of 328	  
these agents. All four compounds strongly inhibited PRK2, ROCK2, RSK1, MSK1 and RSK2. It 329	  
is conceivable that overlapping targets are responsible for shared effects of all four compounds. 330	  
To try and delineate why Y-27632 ROCKi was the most potent compound in increasing the cell 331	  
numbers, we looked for the kinases that ROCKi modulated in a distinct way. A striking candidate 332	  
is p70 ribosomal protein S6 kinase (S6K1), that was strongly inhibited by Pinacidil, HA1077 and 333	  
H-89 but not Y-27632. Targeted deletion of S6K1 in murine ESCs led to slower growth rate of 334	  
the cells, indicating that S6K1 has a positive effect on cell proliferation [26]. Another interesting 335	  
target is protein kinase B alpha (PKBα/AKT). PKBα has a critical role in promoting cell 336	  
survival, proliferation and growth. Ablation of PKBα activity impaired cell proliferation [27], 337	  
whereas the overexpression of constitutively activated PKBα resulted in a malignant phenotype 338	  
of NIH3T3 cells [28]. Finally, constitutively activated PKBα sufficiently maintained 339	  
pluripotency in mouse and primate ESCs [29]. Thus, it is conceivable that inhibition of S6K1 and 340	  
PKBα by Pinacidil, HA1077 and H-89 lessens their potency in increasing cell numbers compared 341	  
to Y-27632 ROCKi which does not inhibit these targets.  342	  
The methods described here should facilitate the use of hESCs in a wide variety of 343	  
quantitative assays from drug screening to the investigation of basic cellular processes. 344	  
Understanding pathways involved in hESC survival will have a major impact for optimization of 345	  
culture conditions that would enable efficient expansion of hESC on a large scale and relieve 346	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selective pressure currently present in hESC cultures that results in the appearance of genetically 347	  
abnormal cells after a prolonged period of growth and expansion in vitro [30,31]. Finally, 348	  
elucidation of mechanisms of hESC survival will be important for eliminating the risk of tumor 349	  
formation if hESCs are to be used in cell replacement therapies [32]. The use of image-based 350	  
multivariate quantitative cellular assays is likely to play an increasingly important role in the 351	  
investigation of the basic biology and methods to differentiate hESCs to therapeutically useful 352	  
tissues. 353	  
354	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4. MATERIALS AND METHODS 354	  
 355	  
4.1. HESC culture 356	  
HESC lines Shef4, Shef5, Shef6, and Shef7 were provided by Professor Harry Moore, University 357	  
of Sheffield [33]. H7 cell line was obtained from Dr James Thomson, University of Wisconsin. 358	  
The H7S14 subline was isolated at the University of Sheffield, 15 passages after original 359	  
derivation. The Shef4-GFP line was created using pCAGeGFP vector as previously described 360	  
[34]. HESC lines were maintained on mitotically-inactivated mouse embryonic fibroblasts as 361	  
previously described [34]. 362	  
 363	  
4.2. Compound libraries and chemicals 364	  
Compounds used in the primary screen were assembled from two commercial libraries: (i) 80 365	  
protein kinase inhibitors used were from a Protein Kinase Inhibitor library (BIOMOL, Enzo Life 366	  
Sciences, Exeter, UK; http://www.biomol.com) and (ii) 960 compounds were from the Prestwick 367	  
Chemical Library (Prestwick Chemical, Illkirch, France; http://www.prestwickchemical.com), 368	  
enriched with marketed drugs. All of the compounds used in the screen are listed in 369	  
Supplementary Table 2. All-trans retinoic acid, pinacidil monohydrate, glibenclamide, 370	  
cromakalim, prednisolone, 6-alpha methylprednisolone, betamethasone and dexamethasone were 371	  
purchased from Sigma-Aldrich. P1075 was purchased from Tocris Bioscience (Bristol, UK). 372	  
 373	  
4.3. High-content primary screening assay  374	  
Shef4 hESC were dissociated to single cells using a 1:3 solution of Accutase (Milipore) in PBS. 375	  
6000 cells were seeded in 96-well plates on feeders in the presence of compounds (10µM for 376	  
compounds from Protein Kinase Inhibitor library and 2.5µg/ml (~5µM) for compounds from the 377	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Prestwick Chemical library. Each compound was assessed in triplicate wells. Control wells 378	  
containing 0.1% DMSO as well as 10µM all-trans retinoic acid were included on each plate. 379	  
After 5 days, cells were fixed with 4% paraformaldehyde. Cells were incubated with TRA-1-60 380	  
(1:10)	  [8] primary antibody followed by incubation with the FITC-conjugated secondary 381	  
antibody (goat anti-mouse IgG+M, Invitrogen). Nuclei were counter stained with 10µg/ml 382	  
Hoechst 33342 (Invitrogen). Each plate included control wells that were stained with Hoechst 383	  
33342 and secondary antibody only, to determine the background fluorescence levels of 384	  
secondary antibody. Images of stained cells were acquired using an automated microscopy 385	  
platform (InCell Analyzer 1000, GE Healthcare). Images were analyzed using Developer 386	  
Toolbox 1.7 software (GE Healthcare).  387	  
The Z’ factor is a dimensionless parameter used to evaluate the performance of a 388	  
screening assay [11]. To calculate the Z’ factor, 30 wells of a 96-well plate were treated with 389	  
0.1% DMSO as negative control, and 30 wells were treated with 10µM all-trans retinoic acid as 390	  
positive control. The Z’ factor was calculated using the following formula: 1 – [(3*SD (DMSO 391	  
control) + 3*SD (all-trans retinoic acid control)/(mean (DMSO control) – mean (all-trans 392	  
retinoic acid control)] [11]. 393	  
 394	  
4.4. Immunocytochemistry for OCT4 protein 395	  
Cells were fixed with 4% paraformaldehyde and after blocking for 1 hour, permeabilized with 396	  
0.1% Triton-X for 1 h at 4°C. Cells were then incubated with an anti-OCT4 primary antibody 397	  
(1:200, Oct4A, rabbit monoclonal, C52G3, Cell Signaling Technology). Secondary antibody used 398	  
was Dylight-488-conjugated anti-rabbit IgG antibody (1:100, Stratech Scientific). Nuclei were 399	  
counter stained with 10µg/ml Hoechst 33342 (Invitrogen). 400	  
	  	   20	  
 401	  
4.5. Cell growth analysis 402	  
For growth curve analysis, dissociated Shef4 hESC were plated in 96-well plates on feeders as 403	  
described above. Cells were fixed with 4% paraformaldehyde at various times after seeding and 404	  
stained with 10µg/ml Hoechst 33342 (Invitrogen). Plates were imaged using the InCell Analyzer 405	  
1000 (GE Healthcare) and images were analyzed for number of hESC using Developer Toolbox 406	  
1.7 software (GE Healthcare) as described above. 407	  
 408	  
4.6. Flow cytometry and cell sorting 409	  
For the analysis of cell-surface markers, cells were harvested using trypsin and resuspended in 410	  
wash buffer (PBS supplemented with 10% foetal calf serum). Staining for OCT4 was performed 411	  
on cells fixed with 4% paraformaldehyde and permeabilized with 0.3% Triton-X for 15 min at 412	  
RT. 5x105 cells were incubated with a primary antibody (1:10, SSEA3, TRA-1-60 and SSEA-1; 413	  
1:200 Oct4A, rabbit monoclonal, C52G3, Cell Signaling Technology) for 1 hour. After washing 414	  
three times with wash buffer, in the case of SSEA3, TRA-1-60 and SSEA-1, cells were labelled 415	  
with FITC-conjugated goat anti-mouse antibody (1:150, Invitrogen) and in the case of OCT4 416	  
with Dylight-488-conjugated anti-rabbit IgG antibody (1:100, Stratech Scientific) for 1 hour. 417	  
This was followed by washing the cells three times with wash buffer and analyzing cell 418	  
fluorescence on a CyAnADP O2 flow cytometer (Dako). The gate for FITC-positive cells was set 419	  
using control cells that were incubated with secondary antibody only. Cell sorting for SSEA3-420	  
positive cells was achieved with 107 cells in a MoFlo Cell Sorter (Dako). 421	  
  422	  
4.7. Cell attachment assay 423	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Shef4-GFP cells were dissociated to single cells and 5000 cells were seeded in 96-well plates on 424	  
feeders in the presence of test compounds or control. At various time points after plating the 425	  
cells, media was removed and cells were washed with PBS to remove unattached cells. Cells 426	  
were imaged for GFP fluorescence using the InCell Analyzer 1000. Developer Toolbox 1.7 427	  
software was used to determine the number of cells per well and the cell area. 428	  
 429	  
4.8. Annexin V apoptosis assay 430	  
Shef4 hES cells were dissociated to single cells with trypsin and 106 cells were seeded onto 10 431	  
cm diameter non-adhesive dishes (Sterilin) in complete hESC medium supplemented with 0.1% 432	  
(v/v) DMSO (control) or 100µM Pinacidil. Cells were harvested at 1, 2, 3 and 4 hours after 433	  
seeding, and analysed for apoptosis using human Annexin V: FITC conjugate according to 434	  
manufacturer’s protocol (Invitrogen). Briefly, 105 cells were harvested, washed once with PBS 435	  
and once with binding buffer (10 mM HEPES, 140 mM NaCl; 2.5 mM CaCl2, pH 7.4) and then 436	  
incubated with 20 µl of Annexin V-FITC for 20 minutes at room temperature, in the dark. 437	  
Propidium iodide (10µg/ml) (Sigma-Aldrich) was added to each sample followed by analysis of 438	  
cell fluorescence on a CyAnADP O2 flow cytometer (DakoCytomation, Glostrup, Denmark). 439	  
 440	  
4.9. Feeder-free cultures 441	  
For assaying effects of Pinacidil in feeder-free conditions, hESC colonies were manually picked 442	  
and transferred to plates coated in Matrigel (BD Biosciences). Media used in this assay were 443	  
either feeder-conditioned media supplemented with 8ng/ml bFGF (Invitrogen), or mTESR 444	  
Maintenance Medium (StemCell Technologies). For single cell cultures, hESC colonies were 445	  
dissociated to single cells using Accutase (Milipore) as described above. 446	  
 447	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4.10. Embryoid body differentiation 448	  
Shef4 hESC were treated with 1% collagenase type IV (Invitrogen) for 10-20 minutes at 37°C 449	  
and scraped off the flask. The detached cells were washed once in media and transferred into 450	  
non-adhesive Petri dishes (Sterilin) and incubated at 37°C and 5% CO2. The differentiation media 451	  
used was the same as media for hESC maintenance but without bFGF.  452	  
 453	  
4.11. RNA Extraction, Reverse Transcriptase reaction, PCR and quantitative PCR 454	  
Total RNA was extracted using TRIzol Reagent (Invitrogen) according to manufacturer’s 455	  
instructions. First-strand cDNA was synthesized SuperScript II reverse transcriptase (Invitrogen) 456	  
or RevertAid H Minus MMuLV Reverse Transcriptase (Fermentas, York, UK), according to 457	  
manufacturer’s instructions. PCR was performed using gene-specific primers and Taq 458	  
polymerase (Invitrogen), in 25 µl PCR reactions, according to manufacturer’s instructions. 459	  
Human heart cDNA that was used as a control for ABCC9 amplification was purchased from 460	  
PrimerDesign (Southampton, UK). For qPCR reactions, 1µl of cDNA template in a 20 µl reaction 461	  
volume containing 2x SYBR Green JumpStart Taq Ready Master Mix (Sigma) and 4 pmoles of 462	  
each of the forward and reverse primer was used. Reactions were run on an iCycler iQ (Bio-Rad 463	  
Laboratories). Each sample was tested in triplicate. The expression of GAPDH was used to 464	  
normalise the samples. Sequences of primers were obtained either from published studies or 465	  
selected from target sequences using the Primer3 program (http://frodo.wi.mit.edu/primer3) and 466	  
are listed in Supplementary Table 4. 467	  
 468	  
4.12. Karyotyping 469	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The karyotype analysis was performed using standard G-banding techniques. Cells cultured in a 470	  
T25 flask were treated with 0.1µg/ml Colcemid (Invitrogen) for up to 4 hours, followed by 471	  
dissociation with 0.25% trypsin/versene (Gibco). The cells were pelleted via centrifugation and 472	  
re-suspended in pre-warmed 0.0375M KCl hypotonic solution and incubated for 10 minutes. 473	  
Following centrifugation the cells were re-suspended in fixative (3:1 methanol:acetic acid). 474	  
Metaphase spreads were prepared on glass microscope slides and G-banded by brief exposure to 475	  
trypsin and stained with 4:1 Gurr’s/Leishmann’s stain (Sigma). A minimum of 10 metaphase 476	  
spreads were analysed and a further 20 counted. 477	  
 478	  
4.13. Protein kinase activity assays 479	  
Examination of the dose-dependant effect of Pinacidil on ROCK2 kinase as well as the screen of 480	  
Pinacidil activity on a panel of 105 kinases were performed by National Centre for Protein 481	  
Kinase Profiling, MRC Protein Phosphorylation Unit, Dundee (www.kinase-screen.mrc.ac.uk), 482	  
as previously described [15]. 483	  
484	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Figure Legends: 617	  
 618	  
Figure 1. High-content screening assay of hESC colonies. (a) Automated image acquisition of 619	  
four fields in each of the wells of a 96-well plate for (b) Hoechst 33342 fluorescence (staining 620	  
nuclei of the cells) and (c) FITC fluorescence (for antibody against the TRA-1-60 antigen). (d) 621	  
Nuclei are segmented based on Hoechst 33342 fluorescence. (e, f) Elimination of feeder cells 622	  
from images by dilation of segmented nuclei and application of size and nuclear staining intensity 623	  
as criteria for exclusion. (g) Identification of TRA-1-60 positive cells by overlaying nuclear 624	  
segmentation image with the image of TRA-1-60 staining. (h) TRA-1-60-positive cells are 625	  
determined on the basis of FITC intensity. TRA-1-60 positive cells are indicated in red and 626	  
negative ones in blue. (i) The data for hESC numbers per colony and TRA-1-60-positive cells per 627	  
colony are obtained by overlaying the colony segmentation image with the image of cells positive 628	  
for TRA-1-60. (j) Resulting measures extracted from images. 629	  
 630	  
Figure 2. Results of the primary screen on hESCs. (a) Layout of primary screen on hESCs for 631	  
identifying compounds that promote differentiation or increase cell numbers. 1040 compounds 632	  
were screened and 44 hits identified. 28 were hits that induced differentiation (~1.8% of total) 633	  
and 16 were hits that increased cell numbers (~1.5% of total). (b) Pie chart shows a significant 634	  
enrichment of steroids amongst the hits that induced differentiation. (c) Kinase inhibitors were 635	  
over-represented amongst the compounds that increased cell numbers. (d) Effect of compounds 636	  
on hESC numbers. Each dot on the graph represents mean of triplicate for 1040 compounds 637	  
tested. Five circled outliers are kinase inhibitors (Y-27632, HA1077, H-89 and HA1004) and the 638	  
potassium channel opener Pinacidil. (e-j) Comparison of information obtained from a classical 639	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high throughput assay (e,f) with additional information obtained from a high-content, high-640	  
throughput assay (g-j) for steroid hits: (e) %TRA-1-60 positive cells, (f) number of cells, (g) 641	  
number of colonies, (h) colony area, (i) intensity levels of Hoechst 33342 nuclear staining, and 642	  
(j) colony form factor. Results shown are mean of triplicates ± SEM. (k) Representative images 643	  
of the effects of steroids (lower panel) versus vehicle control (upper panel) on hESC numbers and 644	  
colony appearance (inset) in the primary screen. Cells are stained for Hoechst 33342. 645	  
 646	  
Figure 3. Induction of hESC differentiation by steroids. (a) Immunocytochemistry for the OCT4 647	  
marker of pluripotency 7 days after treatment with 100µM betamethasone or dexamethasone. (b) 648	  
Typical examples of flow cytometry for SSEA3, TRA-1-60 and OCT4 after 7-day treatment of 649	  
Shef4 cells with 100µM steroid compounds, 10µM all-trans retinoic acid or 0.1% DMSO control. 650	  
(c) RT-PCR analysis of lineage-specific markers after 7-day treatment of Shef4 cells with 100µM 651	  
steroid compounds, 10µM all-trans retinoic acid or 0.1% DMSO control. 652	  
 653	  
Figure 4. Effect of Pinacidil on Shef4 hES cell numbers. (a) An equivalent number of Shef4 cells 654	  
(50000 cells) were seeded onto Matrigel-coated 12-well plates, in mTESR medium supplemented 655	  
with either 0.1% DMSO (left panel) or 100µM Pinacidil (right panel). Two days after initial 656	  
exposure to Pinacidil, there was a marked increase in hESC numbers. Nuclei are stained with 657	  
Hoechst 33342. (b) Growth curves of Shef4 cells in different concentrations of Pinacidil added at 658	  
the time of plating. Values shown are mean of triplicate ± SD. (c) Appearance of Shef4-GFP cells 659	  
1 and 6 hours after plating in Pinacidil-containing media. 100µM Pinacidil-treated wells had 660	  
more cells and cells seemed more flattened out compared to the control. (d) Monitoring cell 661	  
attachment in the presence of Pinacidil by counting attached cells at various times after plating. 662	  
Results are mean of six replicates ± SD. ***P<0.001, Student’s t test. (e) Quantifying cell area of 663	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Pinacidil-treated cells. Results are mean of six replicates ± SD. *P<0.05, ***P<0.001, Student’s t 664	  
test. (f) Annexin V staining in dissociated Shef4 cells exposed to 100µM Pinacidil for various 665	  
lengths of time. Results are mean of duplicates ± SD. *P<0.05, **P<0.005, Student’s t test.  666	  
 667	  
Figure 5. Effect of Pinacidil on hESC pluripotency. (a) Flow cytometry analysis of cell surface 668	  
markers after culturing cells in presence of 100µM Pinacidil for 5 days. (b) Quantitative PCR 669	  
analysis for POU5F1 (OCT4), NANOG and SOX2 markers of pluripotency. Results shown are 670	  
mean of duplicate ± SEM. (c) RT-PCR analysis of embryoid bodies induced in the presence of 671	  
100µM Pinacidil versus control cells. (d) RT-PCR analysis of cells grown for 8 passages in the 672	  
presence of 0.1% DMSO vehicle control or 100µM Pinacidil (left lanes), and after differentiation 673	  
of these cells in embryoid bodies (right lanes). (e) Representative karyotype of Shef4 cells after 674	  
22 passages in 100µM Pinacidil. 675	  
 676	  
Figure 6. Pinacidil action on hESC numbers is KATP channel-independent. (a) RT-PCR analysis 677	  
of ABCC9 expression in hESC (upper panel). Human heart cDNA was used as a positive control. 678	  
The GAPDH housekeeping gene was used as a positive control for RT-PCR (lower panel). (b) 679	  
KATP channel blocker glibenclamide at 100µM did not diminish effect of various concentrations 680	  
of Pinacidil on hESC numbers. Results are mean of six replicates ± SD. (c) Several other known 681	  
KATP channel openers (P1075, minoxidil, nicorandil, cromakalim, diazoxanide) were tested on 682	  
hESC but did not show similar effect to Pinacidil (black bar). Results are mean of six replicates ± 683	  
SD. (d) Pinacidil inhibits Rho-kinase in a dose-dependant manner. (e) The specificity of Pinacidil 684	  
amongst protein kinases. Results are presented as the percentage activity in the presence of 685	  
100µM Pinacidil compared with control incubations (mean of duplicate measurements ± SD). 686	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Kinases inhibited by Pinacidil to less than 10% of control activity are indicated in red, while 687	  
those inhibited by 10-50% are indicated in blue. 688	  
 689	  
Figure 7. Comparison of activity and molecular targets of survival compounds identified in the 690	  
screen. (a) Effect of the five survival compounds tested on Shef4 hESC numbers after 5 days of 691	  
growth in a range of concentrations (1-100µM). Results are mean of triplicate ± SD. (b) 692	  
Administration of survival compounds in combinations had no additive effect on hESC numbers. 693	  
Results are mean of triplicate ± SD. (c) Representative images of Shef4-GFP 6 hours after plating 694	  
the cells in compound-containing media. (d) Comparison of protein kinases that are inhibited by 695	  
Pinacidil and Y-27632 ROCKi. Shared targets are in the lower left quadrant whereas kinases 696	  
inhibited by Pinacidil only are in the top left quadrant. (e) A heatmap created by clustering the 697	  
data on percentage activity of protein kinases in the presence of Pinacidil, Y-27632, HA1077 and 698	  
H-89.  699	  
 700	  
Supplementary Figure S1. Immunocytochemistry for the cell surface antigen TRA-1-60 on a 701	  
hESC colony. The cells express TRA-1-60 when they are in an undifferentiated state (left panel). 702	  
Induction of differentiation by treatment with all-trans retinoic acid for 5 days results in loss of 703	  
TRA-160 expression in most cells (right panel). 704	  
 705	  
Supplementary Figure S2. Monitoring the behaviour of Shef4 cells upon Pinacidil treatment 706	  
using time-lapse microscopy. (a) Selected frames from the videos showing cells at the time of 707	  
plating (t = 0h) (upper panels) and the same fields 72 hours later (t = 72h) (lower panels). The 708	  
Pinacidil-containing well had more cells compared to the vehicle control (lower panels) at the 709	  
end of the experiment, although the same number of cells was seeded in both wells (12500 cells). 710	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(b) Examples of lineage trees generated by manual tracking of individual hESCs (denoted A-F) 711	  
in time-lapse images. Horizontal lines represent the duration of the cell’s existence before 712	  
dividing (vertical lines) or dying. d1, and d2 denote the first and the second cell division of the 713	  
root cell, respectively. (c) The proportion of single cells that survived replating was calculated by 714	  
tracking and scoring all individual cells recorded by time-lapse microscopy. Results represent 715	  
mean ± SD of measurements from 3 fields imaged (n=53 for control cells; n=30 for Pinacidil-716	  
treated cells) *P<0.05, Student’s t test. (d) Cell cycle time of individual cells was calculated from 717	  
the length of horizontal lines between d1 and d2. The time that lapses between the first and the 718	  
second division is not significantly different in Pinacidil-treated and control cells. Boxes 719	  
correspond to the 25 and 75 percentile, and median is shown by the black bar. Whiskers extend to 720	  
the minimum and maximum values.  721	  
 722	  
Supplementary Figure S3. Effect of the five survival compounds on cell attachment. (a) 723	  
Compounds were added at increasing concentrations (1-100µM) at the time of plating and the 724	  
number of attached cells was measured 6 hours later. Results are mean of triplicate ± SD. (b) 725	  
Administration of survival compounds in combinations had no additive effect on hESC 726	  
attachment. Results are mean of triplicate ± SD.	  727	  
